Adam Townsend serves as the Chief Commercial Officer at Apellis Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative therapies for diseases driven by the complement system. In his role, Townsend is responsible for overseeing the company's commercial strategy and operations, including the launch and market expansion of Apellis' groundbreaking treatments. His leadership has been instrumental in guiding the company through the complex landscape of pharmaceutical commercialization. Townsend brings a wealth of experience to Apellis, having held senior leadership positions at several prominent pharmaceutical companies. Prior to joining Apellis, he served as the Senior Vice President and Chief Commercial Officer at Acceleron Pharma, where he played a key role in the successful launch of a novel treatment for pulmonary arterial hypertension. Before that, Townsend spent over a decade at Sanofi, where he held various commercial leadership roles, including Vice President of U.S. Marketing for their Specialty Care business unit. His extensive background in launching and growing innovative therapies has been a valuable asset to Apellis as the company continues to advance its pipeline of complement-targeted therapies. Under Townsend's leadership, Apellis has made significant strides in bringing its first product, EMPAVELI, to market for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder. He has been instrumental in building a strong commercial team and infrastructure to support the successful launch and ongoing growth of EMPAVELI. As Apellis continues to develop and advance its pipeline of potential treatments for a range of complement-mediated diseases, Townsend's strategic vision and commercial expertise will be crucial in driving the company's long-term success and delivering life-changing therapies to patients in need.